Polar Capital Holdings’s Pacira BioSciences PCRX Stock Holding History

Polar Capital Holdings’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-910,455	Closed	-$21.8M	–	291
2025 Q2	$21.8M	Buy	+910,455	New	+$22.9M	0.11%	134
2023 Q4	–	Sell	-8,705	Closed	-$267K	–	300
2023 Q3	$267K	Hold	8,705	–	–	﹤0.01%	273
2023 Q2	$349K	Sell	8,705 -3,890	-31%	-$161K	﹤0.01%	278
2023 Q1	$514K	Hold	12,595	–	–	﹤0.01%	282
2022 Q4	$486K	Hold	12,595	–	–	﹤0.01%	292
2022 Q3	$670	Buy	12,595 +4,000	+47%	+$222K	﹤0.01%	320
2022 Q2	$501	Buy	8,595 +5,250	+157%	+$344K	﹤0.01%	342
2022 Q1	$255	Sell	3,345 -14,023	-81%	-$935K	﹤0.01%	411
2021 Q4	$1.04K	Hold	17,368	–	–	﹤0.01%	334
2021 Q3	$973	Hold	17,368	–	–	﹤0.01%	319
2021 Q2	$1.05K	Buy	+17,368	New	+$1.1M	﹤0.01%	322

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Polar Capital Holdings's PCRX Position: Q3 2025 in Review

Polar Capital Holdings sold out of Pacira BioSciences (PCRX) in Q3 2025, closing a stake of 910,455 shares — an estimated $21.8M sold.

Polar Capital Holdings first reported a position in PCRX in Q2 2021 and held it in 11 quarters. The position peaked at $21.8M in Q2 2025. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2025.

Polar Capital Holdings reported no remaining Pacira BioSciences position as of Q3 2025 after selling out during the quarter.
Polar Capital Holdings sold 910,455 Pacira BioSciences shares in Q3 2025, an estimated $21.8M.
Polar Capital Holdings first reported a position in Pacira BioSciences in Q2 2021 and held it in 11 quarters.
Polar Capital Holdings's Pacira BioSciences position peaked at $21.8M in Q2 2025.
239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2025.

Based on Polar Capital Holdings's 13F filing for Q3 2025, filed 14 Nov 2025.